Goldman Sachs Sees 61% Upside in MAKO (MAKO)

Goldman Sachs lowered its price target on MAKO Surgical (NASDAQ: MAKO) but kept its Buy rating and still sees 61% upside to its new price target of $36 (down from $42).

Comments come after meetings with management and physicians at the Current Concepts in Joint Replacement (CCJR) meeting.

Goldman sees substantial upside and continues to view the company as a attractive fundamental and strategic asset. They also said several of the factors negatively impacting results are likely to prove transient and execution should improve.

The firm adjusted FY12 EPS from ($0.71) to ($0.73), FY13 from $0.01 to ($0.02) and FY14 from $0.42 to $0.43.

For an analyst ratings summary and ratings history on MAKO Surgical click here. For more ratings news on MAKO Surgical click here.

Shares of MAKO Surgical closed at $22.42 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Canaccord Genuity Downgrades Antofagasta Plc. (ANTO:LN) (ANFGF) to Hold
• Moncler SpA (MONC:IM) (MONRY) PT Raised to EUR68 at Barclays
• WH Smith (SMWH:LN) (WHTPF) PT Lowered to GBP15.25 at Barclays